January 08, 2026

Early Symptom Improvements With Nemolizumab in Atopic Dermatitis and Prurigo Nodularis

Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.

Conexiant

January 07, 2026

AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings

Researchers explored whether artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers, according to findings pre...

The ASCO Post

January 07, 2026

Medical Oddities: An Overlooked Existential Flight Risk 

Everyday choices nudged performance, physiology, and risk this week.

Conexiant

January 05, 2026

SGLT-2is Edge GLP-1 RAs on Foot Disease

Danish target trial emulation finds modest neuropathy benefit emerging following year 3, but high discontinuation rates complicate causal interpretation

Conexiant

January 05, 2026

Kiwifruit's Effect on Skin Examined 

Pilot study links 8 weeks of daily consumption to increased epidermal proliferation in patients with low baseline ascorbate

Conexiant

December 23, 2025

The Risks After Cosmetic Surgery

Court records describe missed red flags, delayed escalation, and preventable harm following elective cosmetic surgery.

KFF Health News

December 22, 2025

Small Shingles Risk Seen Post mRNA COVID-19 Booster

Researchers drew from more than 2 million Dutch primary care records.

Conexiant

December 16, 2025

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post

December 15, 2025

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

Conexiant